Cardiac amyloid by cardiovascular magnetic resonance

Suri, A.; Moon, J. C.; Dhamrait, S. S.; Hughes, S.; Holdright, D.
December 2007
Heart;Dec2007, Vol. 93 Issue 12, p1496
Academic Journal
Case Study
The article presents a case study about a man who was treated of cardiac amyloid by cardiovascular magnetic resonance (CMR). It was found that CMR demonstrated reduced long-axis function and global left ventricular subendocardial delayed enhancement suggestive of cardiac amyloid. He was treated with thalidomide-based chemotherapy with the consideration of cardiac transplantation.


Related Articles

  • DO POTENTIAL INTERACTIONS INCREASE THE PROBABILITY FOR A HOSPITALISATION FROM CARDIOVASCULAR REASONS IN HIGH RISK CARDIOVASCULAR PATIENTS IN SLOVAKIA? Foltanova, Tatiana; Thurzo, Martin; Tumova, Ingrid; Lietava, Jan; Svec, Pavel // Biomedical Papers of the Medical Faculty of Palacky University i;2007, Vol. 151, p21 

    An abstract of the medical research "DO POTENTIAL INTERACTIONS INCREASE THE PROBABILITY FOR A HOSPITALISATION FROM CARDIOVASCULAR REASONS IN HIGH RISK CARDIOVASCULAR PATIENTS IN SLOVAKIA?," by Tatiana Foltanova, Martin Thurzo, Ingrid Tumova, Jan Lietava and Pavel Sveca is presented.

  • Fixed dose combinations of cardiovascular drugs. Huffman, Mark D. // BMJ: British Medical Journal;6/7/2014, Vol. 348 Issue 7961, p8 

    The article looks at the findings of the Improving Adherence using Combination Therapy (IMPACT) trial, which demonstrated that fixed-dose combinations of cardiovascular drugs or "polypills" had significantly boosted the self-reported drug adherence rate of trial participants, but did not...

  • Beyond hypertension: Toward guidelines for cardiovascular risk reduction*. Volpe, Massimo; Alderman, Michael H.; Furberg, Curt D.; Jackson, Rodney; Kostis, John B.; Laragh, John H.; Psaty, Bruce M.; Ruilope, Luis M. // American Journal of Hypertension;Nov2004, Vol. 17 Issue 11, p1068 

    Most current clinical guidelines focus primarily on the management of individual cardiovascular risk factors, such as high blood pressure (BP), hypercholesterolemia, or diabetes. A more appropriate clinical approach to reducing cardiovascular disease risk would be based on a comprehensive...

  • Cisplatin/etoposide.  // Reactions Weekly;12/1/2007, Issue 1180, p11 

    The article describes the case of a 33-year-old man who developed cerebral dural sinus thrombosis after receiving cisplatin-based chemotherapy for testicular germ cell cancer. The patient developed repetitive partial seizures, severe headache, , right hemiplegia and bilateral papillary oedema...

  • It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting. Nuriye Özdemir; Hüseyin Abalı; Berna Öksüzoğlu; Burçin Budakoğlu; İlkay Akmangit; Nurullah Zengin // Supportive Care in Cancer;Apr2009, Vol. 17 Issue 4, p399 

    Abstract Goals  It is generally recommended to wait for at least 24 h before starting chemotherapy after implanting venous port catheters (VPC). Our aim was to evaluate whether it is safe to start chemotherapy on the day of implantation. Patients and methods  One hundred eighty...

  • Sirolimus.  // Reactions Weekly;6/25/2005, Issue 1057, p18 

    Discusses research being done on right atrial thrombosis in a heart transplant recipient after initiation of sirolimus. Reference to a study by M. Vanderheyden et al, published in the April 2005 issue of "Acta Cardiologica"; Findings of the study.

  • The First Year Post--Heart Transplantation: Use of Immunosuppressive Drugs and Early Complications. Sulemanjee, Nasir Z.; Merla, Ramanna; Lick, Scott D.; Aunon, Serena M.; Taylor, Melissa; Manson, Melissa; Czer, Lawrence S. C.; Schwarz, Ernst R. // Journal of Cardiovascular Pharmacology & Therapeutics;Mar2008, Vol. 13 Issue 1, p13 

    The article summarizes practices of immunosuppressive drug therapy in the first year post-heart transplant based on the available clinical evidence. Immune suppression aims to avoid and control rejection of the transplanted organ. Percutaneous intravascular endomyocardial biopsies are conducted...

  • Drug Therapy Problem among Patients with Cardiovascular Diseases in Felege Hiwot Referral Hospital, North East, Ethiopia. Tegegne, Gobezie Temesgen; Yimam, Belay; Yesuf, Elias Ali; Gelaw, Belayneh Kefale; Defersha, Amsalu Degu // International Journal of Pharmacy Teaching & Practices (IJPTP);Sep2014, Vol. 5 Issue 3, p989 

    Background: The identification of drug therapy problems is the focus of the assessment and the last decision made in that step of the patient care process. Although drug therapy problem identification is technically part of the assessment process, it represents the truly unique contribution made...

  • Cardiovascular center opens heart transplant office. Alfaro, Aura N. // Caribbean Business;5/6/1999, Vol. 27 Issue 17, p42 

    Reports that the Cardiovascular Center for Puerto Rico and the Caribbean has inaugurated a heart transplant office, the hospital's diagnostic starting point for potential heart transplant candidates, in Rio Piedras. Members of the center's heart transplant program team; Significance of the...


Read the Article


Sign out of this library

Other Topics